Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
Roche's obesity ambition not reliant on one megablockbuster
Roche’s head of metabolic development said the company is firing “on full cylinders” to get a phase 3 trial of its GLP-1/GIP drug launched next year.
James Waldron
Sep 23, 2025 7:45am
Glooko buys Monarch’s EndoTool to enter in-patient diabetes care
Sep 23, 2025 7:30am
Pfizer inks $4.9B Metsera buyout to beef up obesity pipeline
Sep 22, 2025 7:47am
GE HealthCare considering stake sale in China division: report
Sep 18, 2025 2:30pm
Biogen inks $85M Alcyone buyout to acquire drug delivery tech
Sep 18, 2025 10:30am
Roche becomes MASH player via $3.5B deal for 89bio, ph. 3 drug
Sep 18, 2025 5:02am
